Is Stockpiling Protected By Hatch-Waxman Safe Harbor?
Law360, New York (November 21, 2014, 9:54 AM EST) -- Stockpiling of drugs, particularly generic drugs, to allow commercial introduction immediately after patent expiration is common. While infringement suits contesting this conduct are almost nonexistent, it is still considered an act of infringement. The stockpiling of biologics and biosimilars, which are usually more expensive and take longer to produce than typical generics, may bring this dormant issue into the forefront.
Imagine a scenario where a statutory competitor has stockpiled, at great expense, an inventory of biological product, and just before launch the brand strategically sues for patent infringement. This article examines — and challenges — the notion that stockpiling is infringing...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!